Skip to content
Screener

Income Tax at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$1.26M+6,420%
ALN
Alnylam PharmaceuticalsALNY
$13.31M-56.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M0.0%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$545K+581%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$1.69M+320%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$4.04M+83.8%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025Six Months Ended March 31, 2026Six Months Ended March 31, 2025
Other, net(1,609)438(1,332)779
Total other income (expense)3,695(11,586)(8,842)(25,289)
(Loss) income before income tax expense and noncontrolling interest(137,565)369,616(109,293)194,501
Income tax expense71,753351,856
Net (loss) income including noncontrolling interest$(137,572)$367,863$(109,328)$192,645
Net loss attributable to noncontrolling interest, net of tax(4,840)(2,582)(7,409)(4,715)
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.$(132,732)$370,445$(101,919)$197,360
Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's income tax?
Arrowhead Research (ARWR) reported income tax of $7K in Q1 2026.
How has Arrowhead Research's income tax changed year-over-year?
Arrowhead Research's income tax decreased by 99.6% year-over-year, from $1.75M to $7K.
What is the long-term trend for Arrowhead Research's income tax?
Over 2 years (2022 to 2025), Arrowhead Research's income tax has grown at a 137.9% compound annual growth rate (CAGR), from $3.79M to $21.42M.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.

Ask your AI about Arrowhead Research's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude